Basilea Pharmaceutica AG
SIX:BSLN
Intrinsic Value
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. [ Read More ]
The intrinsic value of one
BSLN
stock under the Base Case scenario is
80.95
CHF.
Compared to the current market price of 40.25 CHF,
Basilea Pharmaceutica AG
is
Undervalued by 50%.
Basilea Pharmaceutica AG's market capitalization is 483.1m CHF.
BSLN stock price is 40.25 CHF.
BSLN stock price (40.25 CHF) is 50% less than its Intrinsic Value (80.95 CHF).
BSLN stock price (40.25 CHF) is 58% less than its Relative Value (96.13 CHF). Open Relative Valuation
BSLN has upside potential of 74% compared to the average analyst price target.
Open Wall St Estimates
BSLN's Revenue has grown by 7% over the past 12 months.
BSLN has positive Net Debt. This means that the company has more debt (95m CHF) than cash and short-term investments (60m CHF).
BSLN's long-term liabilties (183m CHF) exceed its long-term assets (173m CHF).
BSLN's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 16%.
BSLN's Revenue has been growing by 7% per year for the last 3 years.
BSLN's Revenue is forecast to grow at a rate of 15% per year over the next 3 years.
BSLN has positive Operating Income for the last twelve months.
BSLN has positive Net Income for the last twelve months.
BSLN has a very low three-year average ROIC (Return on Invested Capital): 2%. The company is not efficient at using invested capital to generate operating income.
BSLN's ROE (Return on Equity) has significantly decreased in the last 3 years from 15% to -68%.
BSLN's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -33% to 16%.
BSLN's ROE (Return on Equity) for the past 12 months is negative and is equal to -68%.
BSLN's Altman Z-Score is very high and is equal to 3.3.
BSLN has positive Gross Profit for the last twelve months.
BSLN has positive Free Cash Flow for the last twelve months.
BSLN's short-term assets (152m CHF) exceed its short-term liabilties (48m CHF).
BSLN has negative three-year average ROE (Return on Equity): -34%. The company is not efficient at transforming stockholders' equity into net income.
BSLN's D/E (Debt to Equity) is very low and is equal to -9.54.
BSLN generates enough operating income (19m CHF) to cover interest payments on its debt (10m CHF).
Valuation Backtest
Basilea Pharmaceutica AG
Run backtest to discover the historical profit from buying and selling
BSLN
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Basilea Pharmaceutica AG
Balance Sheet Decomposition
Basilea Pharmaceutica AG
| Current Assets | 152.1m |
| Cash & Short-Term Investments | 59.9m |
| Receivables | 58.1m |
| Other Current Assets | 34.1m |
| Non-Current Assets | 21.1m |
| PP&E | 20.6m |
| Intangibles | 548k |
| Other Non-Current Assets | 44k |
| Current Liabilities | 47.6m |
| Accounts Payable | 5.8m |
| Accrued Liabilities | 17.7m |
| Other Current Liabilities | 24.1m |
| Non-Current Liabilities | 135.7m |
| Long-Term Debt | 95.5m |
| Other Non-Current Liabilities | 40.2m |
Earnings Waterfall
Basilea Pharmaceutica AG
|
Revenue
|
157.6m
CHF
|
|
Cost of Revenue
|
-26.8m
CHF
|
|
Gross Profit
|
130.8m
CHF
|
|
Operating Expenses
|
-111.6m
CHF
|
|
Operating Income
|
19.2m
CHF
|
|
Other Expenses
|
-8.8m
CHF
|
|
Net Income
|
10.5m
CHF
|
Free Cash Flow Analysis
Basilea Pharmaceutica AG
BSLN Profitability Score
Profitability Due Diligence
Basilea Pharmaceutica AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
Score
Basilea Pharmaceutica AG's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
BSLN Solvency Score
Solvency Due Diligence
Basilea Pharmaceutica AG's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Score
Basilea Pharmaceutica AG's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BSLN Price Targets Summary
Basilea Pharmaceutica AG
According to Wall Street analysts, the average 1-year price target for
BSLN
is 70.04 CHF
with a low forecast of 57.57 CHF and a high forecast of 89.25 CHF.
Shareholder Return
BSLN Price
Basilea Pharmaceutica AG
| Average Annual Return | 2.47% |
| Standard Deviation of Annual Returns | 15.81% |
| Max Drawdown | -51% |
| Market Capitalization | 483.1m CHF |
| Shares Outstanding | 12 001 669 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Basilea Pharmaceutica AG
Country
Industry
Market Cap
Dividend Yield
Description
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
Contact
IPO
Employees
Officers
The intrinsic value of one
BSLN
stock under the Base Case scenario is
80.95
CHF.
Compared to the current market price of 40.25 CHF,
Basilea Pharmaceutica AG
is
Undervalued by 50%.
You don't have any saved screeners yet
